Seniors benefit from high-dose flu vaccine, study finds
Researchers, led by Ann R. Falsey, MD, Associate Professor of Medicine at the University of Rochester School of Medicine and Dentistry in New York, tested a high-dose vaccine on more than 2,500 seniors with an average age of 73. They found that the high dose drastically out-performed a normal dose among seniors when it came to influenza A strains. There was no significant statistical difference between low-dose vaccines and high-dose vaccines in preventing influenza B strains.
Researchers also noticed a higher instance of localized irritation around the injection site with the higher dose vaccines. A total of 54% of high-dose recipients experienced irritation, compared with 44% of normal-dose recipients. Irritation was described as temporary and mild, however, and no other complications arose.